2021 Annual Meeting | Clinical Trials Plenary Session

Date Tuesday 04/20/21

Time 10:00 AM - 12:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) H. E. Hinson, MD, MCR, FAAN, Deborah Hall, MD, PhD, FAAN

Topic(s) General Neurology, Autoimmune Neurology, Cerebrovascular Disease and Interventional Neurology, Movement Disorders, Pain, Sleep

CME Available 2.50 CME credits

Program Materials Program Evaluations

Event Timeline
10:00 AM - 10:15 AM EDT	Speaker	ESCAPE-NA1 (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke) Michael Tymianski, MD, PhD, FRCSC
10:15 AM - 10:30 AM EDT	Speaker	Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine Jessica Ailani, MD, FAAN
10:30 AM - 10:45 AM EDT	Speaker	Efficacy and Safety of Lower-Sodium Oxybate in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Idiopathic Hypersomnia Yves Dauvilliers, MD, PhD
10:45 AM - 11:00 AM EDT	Speaker	Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study James F. Howard, Jr., MD, FAAN
11:00 AM - 11:15 AM EDT	Speaker	Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy - Six Month Results from a Multicenter Randomized Controlled Trial Erika Petersen, MD
11:15 AM - 11:30 AM EDT	Speaker	Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Diseas Raúl Martinez-Fernandez
11:30 AM - 11:45 AM EDT	Speaker	Efficacy and Safety Results of the Avalglucosidase alfa Phase 3 COMET Trial in Late-Onset Pompe Disease Patients Hani Kushlaf, MD, FAAN
11:45 AM - 12:00 PM EDT	Speaker	Leriglitazone Improved Progression of Myelopathy-related Symptoms, and Reduced Cerebral Lesions in Patients with Adrenomyeloneuropathy in a Phase 2/3 Clinical Study Reza Seyedsadjadi, MD
12:00 PM - 12:15 PM EDT	Speaker	FINTEPLA (Fenfluramine) Treatment Improves Everyday Executive Functioning in Patients With Lennox-Gastaut Syndrome: Analysis From a Phase 3 Clinical Trial Kim I. Bishop, PhD

Faculty Disclosures
Raúl Martinez-Fernandez	No disclosure on file
Erika Petersen, MD	Erika Petersen, MD has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Nevro. Erika Petersen, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott Neuromodulation. Erika Petersen, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Erika Petersen, MD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vertos. Erika Petersen, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Saluda. Erika Petersen, MD has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for American Society of Pain and Neurosciences. Erika Petersen, MD has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for SynerFuse. Erika Petersen, MD has stock in SynerFuse. Erika Petersen, MD has stock in neuro.42. The institution of Erika Petersen, MD has received research support from Saluda. The institution of Erika Petersen, MD has received research support from Nevro. The institution of Erika Petersen, MD has received research support from ReNeuron. The institution of Erika Petersen, MD has received research support from Neuros. Erika Petersen, MD has received intellectual property interests from a discovery or technology relating to health care.
Hani Kushlaf, MD, FAAN	Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion AstraZeneca Rare Disease. Dr. Kushlaf has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Kushlaf has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi Genzyme.
James F. Howard, Jr., MD, FAAN	Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for arenx . Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron Pharmaceuticals. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ra Pharma (now UCB Biosciences). Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi US. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Academic CME. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for PeerView CME. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Platform Q CME. Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Zai Laboratories. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Medscape CME. Dr. Howard has stock in General Electric dividends. Dr. Howard has stock in Johnson & Johnson dividends. Dr. Howard has stock in Pfizer dividends. An immediate family member of Dr. Howard has stock in GlaxoSmithKline dividends. An immediate family member of Dr. Howard has stock in GE Healthcare dividends. The institution of Dr. Howard has received research support from Alexion Pharmaceuticals. The institution of Dr. Howard has received research support from argenx . The institution of Dr. Howard has received research support from UCB Biosciences. The institution of Dr. Howard has received research support from NIH. The institution of Dr. Howard has received research support from Centers for Disease Control/Research Triangle Institute. The institution of Dr. Howard has received research support from Duke University (DCRI). The institution of Dr. Howard has received research support from Cartestian Therapeutics. Dr. Howard has a non-compensated relationship as a Scientific Advisiory Board member, Committee member with Myasthenia Gravis Foundation of America that is relevant to AAN interests or activities. Dr. Howard has a non-compensated relationship as a Committee member with American Assoc Neuromuscular and Electrodiagnostic Medicine that is relevant to AAN interests or activities.
Jessica Ailani, MD, FAAN	Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GlaxoSmithKline. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gore. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurolief. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scilex. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr. Reddy. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eneura. Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Report. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medscape. The institution of Dr. Ailani has received research support from Satsuma. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Medical Advisor with SELF.
Yves Dauvilliers, MD, PhD	Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel.
Michael Tymianski, MD, PhD, FRCSC	Michael Tymianski, MD, PHD, FRCSC has received personal compensation for serving as an employee of NoNO Inc.. Michael Tymianski, MD, PHD, FRCSC has stock in NoNO Inc.
H. E. Hinson, MD, MCR, FAAN	Dr. Hinson has received personal compensation in the range of $0-$499 for serving as a Consultant for Rapid AI. Dr. Hinson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association.
Deborah Hall, MD, PhD, FAAN	Dr. Hall has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier - Parkinsonism and Related Disorders. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Hall has received research support from Parkinson's Foundation. The institution of Dr. Hall has received research support from CHDI. The institution of Dr. Hall has received research support from Neurocrine. The institution of Dr. Hall has received research support from Uniqure. The institution of Dr. Hall has received research support from SAGE. The institution of Dr. Hall has received research support from NIH.
Reza Seyedsadjadi, MD	Dr. Seyedsadjadi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Seyedsadjadi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DYSIMMUNE DISEASES FOUNDATION. The institution of Dr. Seyedsadjadi has received research support from AAN.
Kim I. Bishop, PhD	Dr. Bishop has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for zogenix. Dr. Bishop has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Medtronic. Dr. Bishop has stock in zogenix.